COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 641
For patients with abnormal Array 22 results implementing
intervention protocols:
Retesting Timeline
Generally, retesting Array 22 is recommended after 6-9 months of
intervention to assess progress and guide ongoing treatment [43].
Progress Indicators
● Reduction in antibody levels, particularly IgM antibodies first
● Improvement in clinical symptoms
● Normalization of other functional markers (breath test, stool
analysis, etc.)
Persistent Abnormalities
If antibodies remain significantly elevated despite intervention,
consider:
● Ongoing bacterial overgrowth that requires different
antimicrobial approach
● Unaddressed root causes (structural issues, motility problems,
etc.)
● Need for more aggressive barrier support or immune
modulation
Conclusion: The Value of Immune Assessment in SIBO and IBS
Array 22 represents a significant advancement in understanding
the immune component of SIBO and IBS. By identifying specific
immune reactions to bacterial toxins and barrier proteins, this test
bridges critical gaps in conventional assessment approaches that
focus primarily on symptoms or bacterial detection alone.
The immune system's response to bacterial overgrowth plays a
central role in symptom development, barrier dysfunction, and
potential progression to systemic illness. By identifying these
641
